I-Mab Biopharma
I-Mab Biopharma, a leading biopharmaceutical company headquartered in China, focuses on the discovery and development of innovative therapies for cancer and autoimmune diseases. Founded in 2015, I-Mab has rapidly established itself in the global biopharma landscape, with significant operational presence in both China and the United States. The company is renowned for its robust pipeline of monoclonal antibodies and proprietary drug candidates, which are designed to address unmet medical needs. Notable achievements include strategic partnerships and collaborations that enhance its research capabilities and market reach. With a commitment to advancing healthcare through cutting-edge science, I-Mab Biopharma continues to position itself as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does I-Mab Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Salt and Mineral Mining industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
I-Mab Biopharma's score of 10 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
I-Mab Biopharma's reported carbon emissions
I-Mab Biopharma, headquartered in China, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their carbon footprint in terms of kg CO2e across Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. However, without specific commitments or targets from I-Mab Biopharma, it is unclear how they plan to address climate change or reduce their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
I-Mab Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
